Journal article
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
Abstract
AIMS: To establish the safety, tolerability and most promising regimen of darexaban (YM150), a novel, oral, direct factor Xa inhibitor, for prevention of ischaemic events in acute coronary syndrome (ACS).
METHODS: In a 26-week, multi-centre, double-blind, randomized, parallel-group study, 1279 patients with recent high-risk non-ST-segment or ST-segment elevation ACS received one of six darexaban regimens: 5 mg b.i.d., 10 mg o.d., 15 mg b.i.d., …
Authors
Steg PG; Mehta SR; Jukema JW; Lip GYH; Gibson CM; Kovar F; Kala P; Garcia-Hernandez A; Renfurm RW; Granger CB
Journal
European Heart Journal, Vol. 32, No. 20, pp. 2541–2554
Publisher
Oxford University Press (OUP)
Publication Date
October 1, 2011
DOI
10.1093/eurheartj/ehr334
ISSN
0195-668X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Acute Coronary SyndromeAdministration, OralAzepinesBenzamidesDose-Response Relationship, DrugDouble-Blind MethodFactor Xa InhibitorsFemaleHemorrhageHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaRisk FactorsSecondary PreventionStrokeThromboembolismTreatment Outcome